This is a multicenter, open-label trial to evaluate the safety and efficacy of inhaled
treprostinil in subjects with pre-capillary pulmonary hypertension (PH) associated with
interstitial lung disease (ILD) including combined pulmonary fibrosis and emphysema (CPFE).
The study will include about 266 patients who completed all required assessments in the
RIN-PH-201 study at approximately 100 clinical trial centers. The study will continue Your
participation in this study is voluntary and will last until you discontinue from the study
or the study ends. The study will continue until each subject reaches the Week 108 visit or
until inhaled treprostinil become commercially available for patients with PH associated with
ILD including CPFE (whichever is sooner).